Recent advancements in anti-migraine drug research: focus on attempts to decrease neuronal hyperexcitability.

Area of Science:

• Neurology
• Pharmacology

Background:

• Migraine is a prevalent, debilitating neurological disorder with significant societal burden.
• Current treatments, like triptans, offer improvement but leave a substantial unmet need for better therapies.
• Historically, migraine treatment focused on meningeal blood vessel pathology, but recent understanding emphasizes abnormal neural function.

Purpose of the Study:

• To review the pathophysiology and pharmacotherapy of migraine.
• To discuss novel anti-migraine drug targets by examining molecular mechanisms of neuronal hyperexcitability.
• To explore emerging therapeutic strategies as reflected in recent patent literature.

Main Methods:

• Literature review of migraine pathophysiology and pharmacotherapy.
• Analysis of molecular mechanisms underlying neuronal hyperexcitability and cortical spreading depression.
• Examination of recent patent literature for novel drug targets and therapeutic approaches.

Main Results:

• Migraine involves increased neuronal excitability and cortical spreading depression.
• Abnormal neural function is increasingly recognized as central to migraine development and attack triggers.
• Novel drug targets are emerging that focus on attenuating migraine-related hyperexcitability.

Conclusions:

• Understanding neural circuit dysfunction offers new avenues for migraine drug development.
• Targeting neuronal hyperexcitability represents a promising strategy to address unmet needs in migraine therapy.
• Recent patents indicate a shift towards neural targets in anti-migraine drug discovery.